subject:(Cancer therapy)

University of Southern California

1. Sankaranarayanan, Ishwarya. Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy.

Degree: MS, Molecular Microbiology and Immunology, 2014, University of Southern California

URL: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll3/id/444516/rec/6030

► B7‐H4 is a member of the B7 family, which is a costimulatory molecule and negatively regulates the immune response of T cells. Its mechanism of… (more)

Subjects/Keywords: cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sankaranarayanan, I. (2014). Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy. (Masters Thesis). University of Southern California. Retrieved from http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll3/id/444516/rec/6030

Chicago Manual of Style (16^th Edition):

Sankaranarayanan, Ishwarya. “Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy.” 2014. Masters Thesis, University of Southern California. Accessed January 16, 2021. http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll3/id/444516/rec/6030.

MLA Handbook (7^th Edition):

Sankaranarayanan, Ishwarya. “Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy.” 2014. Web. 16 Jan 2021.

Vancouver:

Sankaranarayanan I. Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy. [Internet] [Masters thesis]. University of Southern California; 2014. [cited 2021 Jan 16]. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll3/id/444516/rec/6030.

Council of Science Editors:

Sankaranarayanan I. Stable expression of human B7-H4 in a mouse mammary tumor model as a target for cancer immunotherapy. [Masters Thesis]. University of Southern California; 2014. Available from: http://digitallibrary.usc.edu/cdm/compoundobject/collection/p15799coll3/id/444516/rec/6030

University of Otago

2. Mazumder, Aloran. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .

Degree: 2013, University of Otago

URL: http://hdl.handle.net/10523/4070

► Background: Approximately 80% of prostate cancer patients undergoing hormone therapy progress within 12-18 months to a hormone insensitive form of the disease known as hormone… (more)

▼ Background: Approximately 80% of prostate cancer patients undergoing hormone therapy progress within 12-18 months to a hormone insensitive form of the disease known as hormone refractory prostate cancer. The median survival rate is less than 12 months and traditional therapeutic agents have shown little effect on the progression of the disease. The selective estrogen receptor modulator (SERM), raloxifene has been examined in a limited phase ІІ clinical trial and showed anti-tumor properties. The current study investigated the activity of raloxifene on expression of ERα, ERβ, AR, EGFR and caveolin-1. Also the study aimed to see whether synergistic cytotoxicity could be obtained administering raloxifene in combination with the curcumin analogue RL91. Methods: Two different hormone refractory prostate cancer cell lines PC3 and DU-145 were used in the study. PC3 cells were specifically used to understand the role of raloxifene 10 and 15 μM on different receptors such as estrogen receptor α (ERα), estrogen receptor β (ERβ), androgen receptor (AR), epidermal growth factor receptor (EGFR) and caveolin-1. Since raloxifene is a SERM it should primarily target estrogen receptors. We wanted to determine the effect of raloxifene on different receptors. Immunocytochemistry and Western blotting was carried out to analyze the change in receptor localization and quantitative protein expression levels, respectively. To assess the synergistic potential of the combinational therapy, raloxifene 5, 10 μM and RL91 1.5 and 2 μM were measured individually and in combination on PC3 and DU-145 using sulforhodamine B assay. Results: Raloxifene treatment affected the localization of ERβ, EGFR, AR and caveolin-1 in PC3 cells. The drug was shown to increase the translocation of ERβ and EGFR after 6 h of treatment with a maximum difference observed after 48 h. Also, a decreased expression of ERβ and EGFR was shown following 48 h of raloxifene treatment. It also decreased the co-localization of the EGFR and caveolin-1. Apart from this, it also induced vesicle formation and accumulation of cellular content inside the cells. The cytotoxicity assay showed more cytotoxic potential of RL91 compared to raloxifene, however the combination showed synergism with more than 80 % of cell death observed for both PC3 and DU-145 cells following raloxifene 10 μM and RL91 1.5 μM treatment. Conclusions: In HRPC, ER and EGFR mediated signaling is important for the proliferation of the cells. Raloxifene’s modulation of ERβ, EGFR and AR develops a stressed condition for the cells which decreased the proliferation. By this mechanism raloxifene enhances the cytotoxicity elicited by RL91 when administered in combination. Advisors/Committee Members: Rosengren, Rhonda (advisor).

Subjects/Keywords: Therapy against prostate cancer; therapy; prostate; cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mazumder, A. (2013). Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . (Masters Thesis). University of Otago. Retrieved from http://hdl.handle.net/10523/4070

Chicago Manual of Style (16^th Edition):

Mazumder, Aloran. “Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .” 2013. Masters Thesis, University of Otago. Accessed January 16, 2021. http://hdl.handle.net/10523/4070.

MLA Handbook (7^th Edition):

Mazumder, Aloran. “Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer .” 2013. Web. 16 Jan 2021.

Vancouver:

Mazumder A. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . [Internet] [Masters thesis]. University of Otago; 2013. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10523/4070.

Council of Science Editors:

Mazumder A. Raloxifene along with curcumin analogue RL91, a combinational approach against hormone refractory prostate cancer . [Masters Thesis]. University of Otago; 2013. Available from: http://hdl.handle.net/10523/4070

Deakin University

3. Ajji, Parminder Kaur. Functional characterization of a novel ribosome inactivating protein from Momordica balsamina.

Degree: School of Life and Environmental Sciences, 2016, Deakin University

URL: http://hdl.handle.net/10536/DRO/DU:30103049

► This study provides an insight into the cytotoxic potential of natural and recombinant ribosome-inactivating protein (Balsamin) from Momordica balsamina. It explores the molecular mechanism of… (more)

Subjects/Keywords: liver cancer therapy; breast cancer therapy; balsamin

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Ajji, P. K. (2016). Functional characterization of a novel ribosome inactivating protein from Momordica balsamina. (Thesis). Deakin University. Retrieved from http://hdl.handle.net/10536/DRO/DU:30103049

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Ajji, Parminder Kaur. “Functional characterization of a novel ribosome inactivating protein from Momordica balsamina.” 2016. Thesis, Deakin University. Accessed January 16, 2021. http://hdl.handle.net/10536/DRO/DU:30103049.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Ajji, Parminder Kaur. “Functional characterization of a novel ribosome inactivating protein from Momordica balsamina.” 2016. Web. 16 Jan 2021.

Vancouver:

Ajji PK. Functional characterization of a novel ribosome inactivating protein from Momordica balsamina. [Internet] [Thesis]. Deakin University; 2016. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10536/DRO/DU:30103049.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Ajji PK. Functional characterization of a novel ribosome inactivating protein from Momordica balsamina. [Thesis]. Deakin University; 2016. Available from: http://hdl.handle.net/10536/DRO/DU:30103049

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Rutgers University

4. FENG, XING, 1987-. Roles of SETD4 in radiation sensitivity and tumorigenesis.

Degree: PhD, Pharmacology, Cellular and Molecular, 2018, Rutgers University

URL: https://rucore.libraries.rutgers.edu/rutgers-lib/59084/

►

The SET domain protein methyltransferases play a critical role in histone modifications and global epigenetic regulations. Recent evidence suggests that some SET domain proteins may… (more)

Subjects/Keywords: Cancer – Gene therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

FENG, XING, 1. (2018). Roles of SETD4 in radiation sensitivity and tumorigenesis. (Doctoral Dissertation). Rutgers University. Retrieved from https://rucore.libraries.rutgers.edu/rutgers-lib/59084/

Chicago Manual of Style (16^th Edition):

FENG, XING, 1987-. “Roles of SETD4 in radiation sensitivity and tumorigenesis.” 2018. Doctoral Dissertation, Rutgers University. Accessed January 16, 2021. https://rucore.libraries.rutgers.edu/rutgers-lib/59084/.

MLA Handbook (7^th Edition):

FENG, XING, 1987-. “Roles of SETD4 in radiation sensitivity and tumorigenesis.” 2018. Web. 16 Jan 2021.

Vancouver:

FENG, XING 1. Roles of SETD4 in radiation sensitivity and tumorigenesis. [Internet] [Doctoral dissertation]. Rutgers University; 2018. [cited 2021 Jan 16]. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/59084/.

Council of Science Editors:

FENG, XING 1. Roles of SETD4 in radiation sensitivity and tumorigenesis. [Doctoral Dissertation]. Rutgers University; 2018. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/59084/

5. Wright, Robert Clay. ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY.

Degree: 2014, Johns Hopkins University

URL: http://jhir.library.jhu.edu/handle/1774.2/37975

► Prevailing approaches for developing cancer protein therapeutics focus on creating proteins that therapeutically modulate a cancer marker’s function. Such an approach limits the therapeutic mechanism… (more)

▼ Prevailing approaches for developing cancer protein therapeutics focus on creating proteins that therapeutically modulate a cancer marker’s function. Such an approach limits the therapeutic mechanism to those that naturally arise from modulation of the cancer marker and precludes the use of cancer markers for which therapeutic modulation is not feasible. Furthermore, many potential protein therapies lack the desired cancer targeting. The ability to link recognition of any cancer marker with activation of any desired therapeutic function would enormously expand the number of possible protein therapeutics. We have previously engineered a switchable prodrug-activating enzyme that selectively kills human cancer cells that accumulate the cancer marker hypoxia-inducible factor 1α (HIF-1α). This HIF-1α-activated enzyme switch (Haps59) was created by fusing the prodrug-converting enzyme yeast cytosine deaminase (yCD) and the CH1 domain of the p300 protein, which binds HIF-1α. Haps59 autonomously increases its ability to convert the prodrug 5-fluorcytosine (5FC) into the chemotherapeutic 5-fluorouracil (5FU) in a HIF-1α-dependent manner, rendering colon and breast cancer cells more susceptible to the prodrug. However, the difference in 5FC sensitivity between the presence and absence of HIF-1α was not as large as desired. Using a variety of mutagenesis methods, followed by a two-tiered genetic selection for improved switches, we have identified new HIF-1α-activated enzymes that confer E. coli with modest increases in HIF-1α-dependent 5FC toxicity. However, the current bottleneck in further translation of HIF-1α-activated protein switches is screening potential switch candidates in mammalian cells. To accommodate higher throughput, we explored the use of Flp recombinase-mediated isogenic integration. While initial results in this system are promising, these experiments also brought to light the disadvantageous promiscuous binding activity of the CH1 domain, which we further confirmed in E. coli. This promiscuous binding and subsequent off-target activation needs to be examined under normal physiological conditions to pinpoint off-target activity in these potential therapeutics. With relevant aberrant activators identified, further directed evolution can be used to improve the cancer specificity of HIF-1α-activated protein switches. Advisors/Committee Members: Townsend, Craig A (advisor).

Subjects/Keywords: Enzyme Prodrug Therapy; Protein Engineering; Cancer Therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Wright, R. C. (2014). ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY. (Thesis). Johns Hopkins University. Retrieved from http://jhir.library.jhu.edu/handle/1774.2/37975

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Wright, Robert Clay. “ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY.” 2014. Thesis, Johns Hopkins University. Accessed January 16, 2021. http://jhir.library.jhu.edu/handle/1774.2/37975.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Wright, Robert Clay. “ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY.” 2014. Web. 16 Jan 2021.

Vancouver:

Wright RC. ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY. [Internet] [Thesis]. Johns Hopkins University; 2014. [cited 2021 Jan 16]. Available from: http://jhir.library.jhu.edu/handle/1774.2/37975.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Wright RC. ADVANCES IN THE DEVELOPMENT OF HIF-1α-ACTIVATED PROTEIN SWITCHES FOR ENZYME PRODRUG THERAPY. [Thesis]. Johns Hopkins University; 2014. Available from: http://jhir.library.jhu.edu/handle/1774.2/37975

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Georgia Tech

6. Mackey, Megan A. Gold nanoparticles in some chemical and photothermal applications of cancer therapy.

Degree: PhD, Chemistry and Biochemistry, 2013, Georgia Tech

URL: http://hdl.handle.net/1853/52934

► Gold nanoparticles exhibit an array of properties, both intrinsic (chemical) and extrinsic (photothermal), that can be exploited for their use in cancer therapeutics. Owing to… (more)

Subjects/Keywords: Gold nanopartices; Cancer therapy; Photothermal therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mackey, M. A. (2013). Gold nanoparticles in some chemical and photothermal applications of cancer therapy. (Doctoral Dissertation). Georgia Tech. Retrieved from http://hdl.handle.net/1853/52934

Chicago Manual of Style (16^th Edition):

Mackey, Megan A. “Gold nanoparticles in some chemical and photothermal applications of cancer therapy.” 2013. Doctoral Dissertation, Georgia Tech. Accessed January 16, 2021. http://hdl.handle.net/1853/52934.

MLA Handbook (7^th Edition):

Mackey, Megan A. “Gold nanoparticles in some chemical and photothermal applications of cancer therapy.” 2013. Web. 16 Jan 2021.

Vancouver:

Mackey MA. Gold nanoparticles in some chemical and photothermal applications of cancer therapy. [Internet] [Doctoral dissertation]. Georgia Tech; 2013. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/1853/52934.

Council of Science Editors:

Mackey MA. Gold nanoparticles in some chemical and photothermal applications of cancer therapy. [Doctoral Dissertation]. Georgia Tech; 2013. Available from: http://hdl.handle.net/1853/52934

Universiteit Utrecht

7. Tenhagen, M. FGFRs in breast cancer: expression, downstream effects and possible drug targets.

Degree: 2012, Universiteit Utrecht

URL: http://dspace.library.uu.nl:8080/handle/1874/220167

► In the search of new drugs to treat cancer patients, many targeted therapies are being developed. Fibroblast growth factor receptors (FGFRs) are one of the… (more)

Subjects/Keywords: FGFR; breast cancer, targeted therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Tenhagen, M. (2012). FGFRs in breast cancer: expression, downstream effects and possible drug targets. (Masters Thesis). Universiteit Utrecht. Retrieved from http://dspace.library.uu.nl:8080/handle/1874/220167

Chicago Manual of Style (16^th Edition):

Tenhagen, M. “FGFRs in breast cancer: expression, downstream effects and possible drug targets.” 2012. Masters Thesis, Universiteit Utrecht. Accessed January 16, 2021. http://dspace.library.uu.nl:8080/handle/1874/220167.

MLA Handbook (7^th Edition):

Tenhagen, M. “FGFRs in breast cancer: expression, downstream effects and possible drug targets.” 2012. Web. 16 Jan 2021.

Vancouver:

Tenhagen M. FGFRs in breast cancer: expression, downstream effects and possible drug targets. [Internet] [Masters thesis]. Universiteit Utrecht; 2012. [cited 2021 Jan 16]. Available from: http://dspace.library.uu.nl:8080/handle/1874/220167.

Council of Science Editors:

Tenhagen M. FGFRs in breast cancer: expression, downstream effects and possible drug targets. [Masters Thesis]. Universiteit Utrecht; 2012. Available from: http://dspace.library.uu.nl:8080/handle/1874/220167

University of Rochester

8. Stripay, Jennifer L. Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme.

Degree: PhD, 2016, University of Rochester

URL: http://hdl.handle.net/1802/31636

► Glioblastoma multiforme is the most common primary brain tumor in adults, the most malignant of all intracranial tumors, and is associated with inevitable recurrence and… (more)

Subjects/Keywords: Cancer; cbl; Glioblastoma; Redox; Therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Stripay, J. L. (2016). Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme. (Doctoral Dissertation). University of Rochester. Retrieved from http://hdl.handle.net/1802/31636

Chicago Manual of Style (16^th Edition):

Stripay, Jennifer L. “Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme.” 2016. Doctoral Dissertation, University of Rochester. Accessed January 16, 2021. http://hdl.handle.net/1802/31636.

MLA Handbook (7^th Edition):

Stripay, Jennifer L. “Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme.” 2016. Web. 16 Jan 2021.

Vancouver:

Stripay JL. Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme. [Internet] [Doctoral dissertation]. University of Rochester; 2016. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/1802/31636.

Council of Science Editors:

Stripay JL. Targeting a Network of Cancer Control Nodes through Rescue of c-Cbl; A Novel Therapeutic Approach for Glioblastoma Multiforme. [Doctoral Dissertation]. University of Rochester; 2016. Available from: http://hdl.handle.net/1802/31636

University of Alberta

9. Keuling, Angela. Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins.

Degree: PhD, Medical Sciences - Medical Genetics, 2010, University of Alberta

URL: https://era.library.ualberta.ca/files/3t945r78j

► Malignant melanoma is resistant to almost all conventional forms of chemotherapy. Recent evidence suggests that anti-apoptotic proteins of the Bcl-2 family are overexpressed in melanoma… (more)

Subjects/Keywords: apoptosis; cancer therapy; melanoma

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Keuling, A. (2010). Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins. (Doctoral Dissertation). University of Alberta. Retrieved from https://era.library.ualberta.ca/files/3t945r78j

Chicago Manual of Style (16^th Edition):

Keuling, Angela. “Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins.” 2010. Doctoral Dissertation, University of Alberta. Accessed January 16, 2021. https://era.library.ualberta.ca/files/3t945r78j.

MLA Handbook (7^th Edition):

Keuling, Angela. “Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins.” 2010. Web. 16 Jan 2021.

Vancouver:

Keuling A. Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins. [Internet] [Doctoral dissertation]. University of Alberta; 2010. [cited 2021 Jan 16]. Available from: https://era.library.ualberta.ca/files/3t945r78j.

Council of Science Editors:

Keuling A. Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins. [Doctoral Dissertation]. University of Alberta; 2010. Available from: https://era.library.ualberta.ca/files/3t945r78j

10. Walker, David. CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY.

Degree: 2014, Johns Hopkins University

URL: http://jhir.library.jhu.edu/handle/1774.2/37192

► Cancer is a disease of genome alterations that drive uncontrolled growth. The most challenging aspect of cancer treatment is that there are many avenues to… (more)

▼ Cancer is a disease of genome alterations that drive uncontrolled growth. The most challenging aspect of cancer treatment is that there are many avenues to enable proliferation within the cell, including alterations to epigenetic elements. DNA methylation—a methyl modification on the 5-carbon of cytosine bases—has been pinpointed to be one of these avenues, and as such is an option for targeted therapy. DNA methylation at the promoter regions of genes can silence their transcription, and normally-silenced genes that are hypomethylated can be re-expressed. Current approved cancer therapies targeting DNA methylation focus on inhibiting DNA methyltransferases, enzymes responsible for maintaining DNA methylation during division. These therapies, which are effective at reducing methylation levels on DNA globally and at tumor suppressor genes, come at a cost: they are nucleoside analogs that exhibit serious toxicities. The central hypothesis for this thesis is that another DNA methylation maintenance protein, ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) is an attractive candidate for anticancer therapy. UHRF1 directly interacts with DNMT1 and is thought of as a “helper” molecule that recruits DNMTs to newly synthesized DNA. DNA is methylated symmetrically on both strands, but during replication new copies of DNA contain only one strand with the proper methylation information; this so-called hemimethylated state is the target for the Set- and RING-Associated (SRA) domain of UHRF1, which binds this hemimethylated DNA and allows UHRF1 to recruit the DNA methyltransferase machinery to maintain methylation on the newly synthesized strand. To address our hypothesis, we have developed a suite of molecular tools to study the impact of removing UHRF1 on cellular growth, DNA methylation patterns, gene expression and survivability in vitro. We have developed a mouse model for heterozygous deletion of UHRF1 in vivo. We have successfully implemented a UHRF1 inhibitor assay to use on small molecule libraries to identify potential inhibitors. We show that UHRF1 is overexpressed in cancer cell lines and tissue, and when knocked down, reduces growth and survival. We also demonstrate that UHRF1 is necessary for global and local methylation, and that methylation loss due to lower UHRF1 levels results in re-expression of silenced genes. Our mouse model of UHRF1 deletion shows that it is necessary for tumorigenesis in the APCmin model. Finally, we determine that anthracycline derivatives like mitoxantrone and doxorubicin interfere with UHRF1 binding DNA, decrease global methylation in cells and synergize with decitabine in cell killing. Synthesizing these results, we believe that UHRF1 is a viable target for cancer treatment, and effectively inhibiting it can enhance approved DNA methylation chemotherapies for better cancer control. Advisors/Committee Members: Nelson, William G (advisor).

Subjects/Keywords: UHRF1; cancer; epigenetics; epigenetic therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Walker, D. (2014). CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY. (Thesis). Johns Hopkins University. Retrieved from http://jhir.library.jhu.edu/handle/1774.2/37192

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Walker, David. “CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY.” 2014. Thesis, Johns Hopkins University. Accessed January 16, 2021. http://jhir.library.jhu.edu/handle/1774.2/37192.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Walker, David. “CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY.” 2014. Web. 16 Jan 2021.

Vancouver:

Walker D. CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY. [Internet] [Thesis]. Johns Hopkins University; 2014. [cited 2021 Jan 16]. Available from: http://jhir.library.jhu.edu/handle/1774.2/37192.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Walker D. CREDENTIALING THE DNA METHYLATION MAINTENANCE PROTEIN UHRF1 AS A TARGET FOR ANTICANCER THERAPY. [Thesis]. Johns Hopkins University; 2014. Available from: http://jhir.library.jhu.edu/handle/1774.2/37192

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Vanderbilt University

11. Meador, Catherine Belle. Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma.

Degree: PhD, Cancer Biology, 2015, Vanderbilt University

URL: http://hdl.handle.net/1803/13334

► EGFR-mutant lung cancers are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs; erlotinib/gefitinib/afatinib), but tumors develop drug resistance within 9-16 months. Resistance to gefitinib/erlotinib commonly… (more)

▼ EGFR-mutant lung cancers are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs; erlotinib/gefitinib/afatinib), but tumors develop drug resistance within 9-16 months. Resistance to gefitinib/erlotinib commonly occurs via a second-site EGFR mutation, T790M. Two strategies to overcome T790M+ resistance are mutant-specific EGFR TKIs, such as AZD9291, and dual inhibition of EGFR with afatinib plus the anti-EGFR antibody, cetuximab (A+C). Unfortunately, ‘second-line’ acquired resistance to A+C and AZD9291, after ‘first-line’ acquired resistance to erlotinib/gefitinib/afatinib, also occurs. To prevent/delay resistance to AZD9291, the combination of AZD9291 plus selumetinib (MEK1/2 inhibitor; AZD6244/ARRY-142886) is also currently being tested in a Phase I clinical trial (NCT02143466). The effects of sequential and combination treatment with various anti-EGFR agents on tumor evolution and drug resistance are largely unknown. In these studies, we modeled drug resistance pre-clinically to: 1. Assess the heterogeneity of mechanisms of first-line resistance to erlotinib and afatinib 2. Determine the optimum order of treatment with A+C vs. AZD9291 in the setting of T790M+ EGFR-mutant lung tumors 3. Elucidate mechanisms of first- and second-line acquired resistance to AZD9291 and 4. Elucidate mechanisms of resistance to AZD9291 plus selumetinib. Next-generation sequencing of genomic DNA from cell line models of resistance to erlotinib/afatinib revealed multiple potentially functional genomic changes within a given pool of resistant cells (including T790M). We also found that AZD9291 is more potent than A+C at inhibiting cell growth in the setting of T790M+ resistance to erlotinib. A+C-resistant cell lines remain sensitive to AZD9291, but AZD9291-resistant cell lines are cross-resistant to A+C. Resistance to AZD9291 is associated with dysregulation of MAPK signaling and can be overcome by addition of the MEK 1/2 inhibitor, selumetinib. Finally, AZD9291 plus selumetinib-resistant cell lines display increased baseline phospho-MEK/ERK and are sensitive to in vitro treatment with an ERK inhibitor, SCH772984 or alternative MEK inhibitor, trametinib. These studies provide a more comprehensive understanding of how EGFR-mutant tumors undergo rewiring of their signaling circuitry in response to single-agent EGFR- and combined EGFR+MEK-inhibition. This work, emphasizing a mechanistic understanding of the effects of therapies on tumor evolution, provides a framework for future clinical trials testing different treatment sequences. Advisors/Committee Members: Christine Lovly (committee member), Jennifer Pietenpol (committee member), William Pao (committee member), Rebecca Cook (Committee Chair).

Subjects/Keywords: targeted therapy; EGFR; lung cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Meador, C. B. (2015). Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma. (Doctoral Dissertation). Vanderbilt University. Retrieved from http://hdl.handle.net/1803/13334

Chicago Manual of Style (16^th Edition):

Meador, Catherine Belle. “Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma.” 2015. Doctoral Dissertation, Vanderbilt University. Accessed January 16, 2021. http://hdl.handle.net/1803/13334.

MLA Handbook (7^th Edition):

Meador, Catherine Belle. “Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma.” 2015. Web. 16 Jan 2021.

Vancouver:

Meador CB. Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma. [Internet] [Doctoral dissertation]. Vanderbilt University; 2015. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/1803/13334.

Council of Science Editors:

Meador CB. Optimizing the sequence of targeted therapy in EGFR-mutant lung adenocarcinoma. [Doctoral Dissertation]. Vanderbilt University; 2015. Available from: http://hdl.handle.net/1803/13334

Penn State University

12. Yao, Nengliang. Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery.

Degree: 2013, Penn State University

URL: https://submit-etda.libraries.psu.edu/catalog/17428

► Background: Whole breast irradiation (WBI) has been recommended after breast-conserving surgery (BCS) in practice guidelines for definitive local therapy of early stage breast cancers since… (more)

▼ Background: Whole breast irradiation (WBI) has been recommended after breast-conserving surgery (BCS) in practice guidelines for definitive local therapy of early stage breast cancers since 1990, in light of evidence that BCS without radiation is associated with higher local recurrence rates and higher mortality risk. Accelerated partial breast irradiation (APBI) is an alternative to WBI, which significantly decreases the number of patient visits. In contrast to 16-36 doses of radiotherapy in WBI, APBI usually involves twice-daily treatments over 4-5 days. Three important issues related to BCS-related radiation therapy are the focus of this dissertation. First, factors underlying regional disparities in the receipt of radiation after BCS are not well understood. The second issue relates to a knowledge gap about the effect of treatment features on the probability of choosing a treatment among different alternatives. The third issue is the increasing use of brachytherapy APBI among early stage breast cancer patients without conclusive population-based evidence of clinical effectiveness. Objectives: This dissertation includes three related studies that each address a key question related to radiation therapy for early stage breast cancer: (1) What mechanisms underlie geographic variation in the omission of radiation therapy after BCS? (2) What are the effects of treatment characteristics on the probabilities of choosing various alternative local therapies for early stage breast cancer? and (3) What is the comparative effectiveness of brachytherapy ABPI versus WBI among elderly women after BCS? Methods: This dissertation analyzes data from SEER, SEER-Medicare, the Area Resource File, Medicare Local Coverage Determination database, and Census files. Cancer registry codes and Medicare claims codes were used to identify the study cohort and diagnosis and treatment information. Spatial exploratory data analysis, logistic regression, nested logit modeling, log-rank tests, Cox proportional hazards modeling, and instrumental variable analyses were used to address the research questions. Findings: The first study found that metropolitan patients living in counties that have WBI, AAPBI, or both services are more likely to omit radiation after BCS than other patients living in counties without radiation therapy facilities. Study 2 found that treatment alternatives with longer treatment and recovery times and longer travel distances are associated with decreased probability of being chosen. Alternatives recommended by guidelines and covered by Medicare are associated with increased probabilities of being chosen. Study 3 found that the risk of death in patients treated with APBI-Brachy was not significantly different from patients treated with WBI. Factors independently associated with an increased risk of death included older age, invasive cancer, tumor size greater than 2 cm, lymph node involvement, ductal histology, negative estrogen receptor status, undifferentiated tumor, the existence of comorbid conditions, and living in a… Advisors/Committee Members: Marianne Messersmith Hillemeier, Dissertation Advisor/Co-Advisor, Marianne Messersmith Hillemeier, Committee Chair/Co-Chair, Roger T Anderson, Committee Member, Stephen Augustus Matthews, Committee Member, John Raymond Moran Jr., Committee Member, Pamela Farley Short, Committee Member.

Subjects/Keywords: Radiation Therapy; Breast Cancer

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Yao, N. (2013). Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery. (Thesis). Penn State University. Retrieved from https://submit-etda.libraries.psu.edu/catalog/17428

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Yao, Nengliang. “Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery.” 2013. Thesis, Penn State University. Accessed January 16, 2021. https://submit-etda.libraries.psu.edu/catalog/17428.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Yao, Nengliang. “Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery.” 2013. Web. 16 Jan 2021.

Vancouver:

Yao N. Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery. [Internet] [Thesis]. Penn State University; 2013. [cited 2021 Jan 16]. Available from: https://submit-etda.libraries.psu.edu/catalog/17428.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Yao N. Radiation Therapy For Early Stage Breast Cancer After Breast-conserving Surgery. [Thesis]. Penn State University; 2013. Available from: https://submit-etda.libraries.psu.edu/catalog/17428

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Toronto

13. Berinstein, Elliot. The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1.

Degree: 2016, University of Toronto

URL: http://hdl.handle.net/1807/90143

►

The adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has become a promising treatment for various cancers. CARs have been shown to redirect… (more)

Subjects/Keywords: Cancer; Gene Therapy; Immunotherapy; 0992

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Berinstein, E. (2016). The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1. (Masters Thesis). University of Toronto. Retrieved from http://hdl.handle.net/1807/90143

Chicago Manual of Style (16^th Edition):

Berinstein, Elliot. “The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1.” 2016. Masters Thesis, University of Toronto. Accessed January 16, 2021. http://hdl.handle.net/1807/90143.

MLA Handbook (7^th Edition):

Berinstein, Elliot. “The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1.” 2016. Web. 16 Jan 2021.

Vancouver:

Berinstein E. The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1. [Internet] [Masters thesis]. University of Toronto; 2016. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/1807/90143.

Council of Science Editors:

Berinstein E. The Development Of A Novel Chimeric Antigen Receptor Specific For Syndecan-1. [Masters Thesis]. University of Toronto; 2016. Available from: http://hdl.handle.net/1807/90143

Colorado State University

14. Nieset, Jessica Rae. Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer.

Degree: PhD, Environmental and Radiological Health Sciences, 2011, Colorado State University

URL: http://hdl.handle.net/10217/46380

► Urinary bladder cancer is the most common cancer of the canine urinary tract, with transitional cell carcinoma (TCC) being the most commonly diagnosed tumor type.… (more)

▼ Urinary bladder cancer is the most common cancer of the canine urinary tract, with transitional cell carcinoma (TCC) being the most commonly diagnosed tumor type. TCC is aggressive, invasive and fatal for most dogs. If left untreated, TCC of the canine bladder has average survival times less than one year. Optimal treatment of this malignancy remains a topic of debate. Different treatment options exist, but many complicating factors make the probability of cure very low, regardless of treatment type, and most care is palliative in nature. Radiation therapy is a possible treatment option, however dailyshape, size, and positional changes (motion) of the bladder and surrounding soft tissue structures often make this modality difficult to incorporate into a curative-intent treatment plan. This study was designed to investigate and quantify the motion characteristics experienced by the canine urinary bladder from day to day. Additionally, this information was then used to examine possible treatment scenarios and determine which of those scenarios would be optimal for canine bladder cancer patients. Retrospective cone beam CT (CBCT) image data from ten dogs were used in this study. Organs of interest were contoured on each daily treatment CBCT data set and the images, along with the contours, were registered (fused) to the original (reference) planning CT. Quantification of bladder motion was determined by making measurements relative to the planning CT. Dosimetric data for the organs of interest were determined using dose volume histograms generated from sample treatment plans. Results indicate a wide range in bladder motion throughout treatment, which partly depends on the methods used for patient positioning (set-up). Of the three patient positioning methods evaluated (dorsal, sternal, and lateral recumbency), the least amount of bladder variability, as well as lowest rectal dose, is seen when dogs are placed in lateral recumbency. Using these motion characteristics, we were able to develop different treatment planning and set-up scenarios that allow for a curative dose to be delivered to the bladder, while simultaneously reducing the dose delivered to the nearby sensitive rectal tissue. All advanced treatment planning techniques produce a better dose distribution than traditional parallel opposed planning, with adaptive radiation therapy (ART) planning techniques showing the most advantageous dose distribution. These results allow for a more informed approach to the treatment of canine bladder cancer, as well as providing possible curative-intent treatment options for canine patients with this malignancy. Advisors/Committee Members: Harmon, Joseph F. (advisor), Bailey, Susan M. (committee member), LaRue, Susan M. (committee member), Worley, Deanna R. (committee member), Johnson, Thomas E. (Thomas Edward), 1964- (committee member).

Subjects/Keywords: canine bladder cancer; radiation therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Nieset, J. R. (2011). Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer. (Doctoral Dissertation). Colorado State University. Retrieved from http://hdl.handle.net/10217/46380

Chicago Manual of Style (16^th Edition):

Nieset, Jessica Rae. “Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer.” 2011. Doctoral Dissertation, Colorado State University. Accessed January 16, 2021. http://hdl.handle.net/10217/46380.

MLA Handbook (7^th Edition):

Nieset, Jessica Rae. “Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer.” 2011. Web. 16 Jan 2021.

Vancouver:

Nieset JR. Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer. [Internet] [Doctoral dissertation]. Colorado State University; 2011. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10217/46380.

Council of Science Editors:

Nieset JR. Use of cone-beam computed tomography to characterize urinary bladder variations and optimize delivery of radiation therapy for canine bladder cancer. [Doctoral Dissertation]. Colorado State University; 2011. Available from: http://hdl.handle.net/10217/46380

University of Ottawa

15. Watson, Margaret. Characterizing a Novel Viral Sensitizer BI-D1870 .

Degree: 2019, University of Ottawa

URL: http://hdl.handle.net/10393/39364

► Oncolytic viruses (OVs) are an emerging cancer therapy that use an oncotropic virus to selectively infect and kill cancer cells, as well as stimulate long-lasting… (more)

Subjects/Keywords: Oncolytic virus; Cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Watson, M. (2019). Characterizing a Novel Viral Sensitizer BI-D1870 . (Thesis). University of Ottawa. Retrieved from http://hdl.handle.net/10393/39364

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Watson, Margaret. “Characterizing a Novel Viral Sensitizer BI-D1870 .” 2019. Thesis, University of Ottawa. Accessed January 16, 2021. http://hdl.handle.net/10393/39364.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Watson, Margaret. “Characterizing a Novel Viral Sensitizer BI-D1870 .” 2019. Web. 16 Jan 2021.

Vancouver:

Watson M. Characterizing a Novel Viral Sensitizer BI-D1870 . [Internet] [Thesis]. University of Ottawa; 2019. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10393/39364.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Watson M. Characterizing a Novel Viral Sensitizer BI-D1870 . [Thesis]. University of Ottawa; 2019. Available from: http://hdl.handle.net/10393/39364

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Université Catholique de Louvain

16. Barragan Montero, Ana Maria. Robust, accurate and patient-specific treatment planning for proton therapy.

Degree: 2017, Université Catholique de Louvain

URL: http://hdl.handle.net/2078.1/189076

►

The survival statistics for cancer patients treated with radiation therapy using photon beams show that many treatments fail due to poor tumour local control (TLC).… (more)

Subjects/Keywords: Proton therapy; Cancer treatment planning

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Barragan Montero, A. M. (2017). Robust, accurate and patient-specific treatment planning for proton therapy. (Thesis). Université Catholique de Louvain. Retrieved from http://hdl.handle.net/2078.1/189076

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Barragan Montero, Ana Maria. “Robust, accurate and patient-specific treatment planning for proton therapy.” 2017. Thesis, Université Catholique de Louvain. Accessed January 16, 2021. http://hdl.handle.net/2078.1/189076.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Barragan Montero, Ana Maria. “Robust, accurate and patient-specific treatment planning for proton therapy.” 2017. Web. 16 Jan 2021.

Vancouver:

Barragan Montero AM. Robust, accurate and patient-specific treatment planning for proton therapy. [Internet] [Thesis]. Université Catholique de Louvain; 2017. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/2078.1/189076.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Barragan Montero AM. Robust, accurate and patient-specific treatment planning for proton therapy. [Thesis]. Université Catholique de Louvain; 2017. Available from: http://hdl.handle.net/2078.1/189076

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Missouri – Columbia

17. Carroll, Valerie (Valerie Nicole). Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III).

Degree: 2013, University of Missouri – Columbia

URL: https://doi.org/10.32469/10355/37585

► Rhodium-105 is an attractive nuclide for radiotherapeutic applications due to its nuclear properties (566 keV β-, 319 keV [19%], 306 keV [5%]) and the kinetic… (more)

Subjects/Keywords: bifunctional chelate; radiopharmaceutical; cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Carroll, V. (. N. (2013). Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III). (Thesis). University of Missouri – Columbia. Retrieved from https://doi.org/10.32469/10355/37585

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Carroll, Valerie (Valerie Nicole). “Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III).” 2013. Thesis, University of Missouri – Columbia. Accessed January 16, 2021. https://doi.org/10.32469/10355/37585.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Carroll, Valerie (Valerie Nicole). “Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III).” 2013. Web. 16 Jan 2021.

Vancouver:

Carroll V(N. Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III). [Internet] [Thesis]. University of Missouri – Columbia; 2013. [cited 2021 Jan 16]. Available from: https://doi.org/10.32469/10355/37585.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Carroll V(N. Development of a rhodium tetrathioether bombesin analogue and investigation of cyclic and acyclic ligand systems for 105Rh(III). [Thesis]. University of Missouri – Columbia; 2013. Available from: https://doi.org/10.32469/10355/37585

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Melbourne

18. Corona, Silvia Paola. Targeted therapeutics in colorectal cancer.

Degree: 2013, University of Melbourne

URL: http://hdl.handle.net/11343/38615

► Colon cancer still remains the third cause of cancer related death in the western countries. Molecular targeted drugs have revolutionized the approach to cancer therapy… (more)

Subjects/Keywords: colon cancer therapy; targeted therapeutics

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Corona, S. P. (2013). Targeted therapeutics in colorectal cancer. (Doctoral Dissertation). University of Melbourne. Retrieved from http://hdl.handle.net/11343/38615

Chicago Manual of Style (16^th Edition):

Corona, Silvia Paola. “Targeted therapeutics in colorectal cancer.” 2013. Doctoral Dissertation, University of Melbourne. Accessed January 16, 2021. http://hdl.handle.net/11343/38615.

MLA Handbook (7^th Edition):

Corona, Silvia Paola. “Targeted therapeutics in colorectal cancer.” 2013. Web. 16 Jan 2021.

Vancouver:

Corona SP. Targeted therapeutics in colorectal cancer. [Internet] [Doctoral dissertation]. University of Melbourne; 2013. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/11343/38615.

Council of Science Editors:

Corona SP. Targeted therapeutics in colorectal cancer. [Doctoral Dissertation]. University of Melbourne; 2013. Available from: http://hdl.handle.net/11343/38615

19. Servedio, Danielle Lauren. Cancer Patients' Perception of Body Image: A Visual Exploration.

Degree: MA, Marital and Family Therapy, 2012, Loyola Marymount University

URL: https://digitalcommons.lmu.edu/etd/111

► This study explored the impact and trauma that a cancer diagnosis and cancer treatment can have on a women’s image and experience of her… (more)

Subjects/Keywords: Cancer; Body Image; Art therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Servedio, D. L. (2012). Cancer Patients' Perception of Body Image: A Visual Exploration. (Masters Thesis). Loyola Marymount University. Retrieved from https://digitalcommons.lmu.edu/etd/111

Chicago Manual of Style (16^th Edition):

Servedio, Danielle Lauren. “Cancer Patients' Perception of Body Image: A Visual Exploration.” 2012. Masters Thesis, Loyola Marymount University. Accessed January 16, 2021. https://digitalcommons.lmu.edu/etd/111.

MLA Handbook (7^th Edition):

Servedio, Danielle Lauren. “Cancer Patients' Perception of Body Image: A Visual Exploration.” 2012. Web. 16 Jan 2021.

Vancouver:

Servedio DL. Cancer Patients' Perception of Body Image: A Visual Exploration. [Internet] [Masters thesis]. Loyola Marymount University; 2012. [cited 2021 Jan 16]. Available from: https://digitalcommons.lmu.edu/etd/111.

Council of Science Editors:

Servedio DL. Cancer Patients' Perception of Body Image: A Visual Exploration. [Masters Thesis]. Loyola Marymount University; 2012. Available from: https://digitalcommons.lmu.edu/etd/111

University of Waterloo

20. Zhang, Qinrong. A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment.

Degree: 2017, University of Waterloo

URL: http://hdl.handle.net/10012/11272

► Cisplatin is the first and most widely used platinum-based chemotherapy drug and is the cornerstone agent in treating a broad spectrum of cancers, including ovarian… (more)

▼ Cisplatin is the first and most widely used platinum-based chemotherapy drug and is the cornerstone agent in treating a broad spectrum of cancers, including ovarian cancer, testicular cancer, cervical cancer, bladder cancer, lung cancer, head and neck cancer, lymphoma, and brain tumors. It is one of the few curative anti-cancer agents; however, its clinical application is often limited by severe toxic side effects and resistance possessed by some cancers. Our group has recently, through the femtomedicine approach, unraveled a new molecular mechanism of Cisplatin. It has been found that Cisplatin is extremely effective for the dissociative electron transfer (DET) reaction with weakly-bound electrons to produce reactive radicals that cause DNA strand breaks, apoptosis, and final clonogenic cell kill. Based on this DET mechanism, it is proposed that Cisplatin may be administered in combination with a biological electron donor to enhance its chemotherapeutic efficacy. We have tried a few combinations of Cisplatin and electron-donating compounds. In this thesis, we show results of the combination: Cisplatin and Rhodamine-B, the one with the greatest potential as demonstrated in both in vitro assays and in vivo xenograft mouse cancer models. This thesis begins with an introduction to cancer and cancer therapies in Chapter 1, where the theory, objective, and scope of this thesis are introduced. Chapter 2 focuses on some new understandings of Cisplatin-induced DNA damage. In vitro and in vivo experiment results on the effectiveness of the combination of Cisplatin and Rhodamine-B are presented in Chapter 3 and Chapter 4, respectively. In Chapter 5, time-resolved femtosecond laser spectroscopic studies on the reaction between Cisplatin and Rhodamine-B are shown. Chapter 6 as the last Chapter summarizes results obtained in this project and proposes some possible future research. In vitro experiments confirm the potential of this proposed combination of Cisplatin and Rhodamine-B to treat cancer. From cell survival tests, by applying MTT assays and clonogenic assays, it has been shown that our proposed combination significantly enhances the cell-killing efficacy in cancer cells; but surprisingly, not in normal cells. Besides, plasmid DNA gel electrophoresis and γ-H2AX staining in treated cells indicate that more double-strand breaks can be induced using our combination, compared to Cisplatin only. In addition, measurements on Caspase 3/7 activation and Annexin V-FITC labeling flow cytometry experiments clearly show a significant enhancement in the population of apoptotic cells using our combination. To further verify the effectiveness of the combination of Cisplatin and Rhodamine-B, in vivo xenograft mouse models have been developed. Our combination greatly enhances the tumor growth inhibition and even tumor shrinkage in three different mouse models. Acute toxicity analysis and body weight measurements do not show additional side effects induced by the addition of Rhodamine-B. Lastly, spectroscopic measurements…

Subjects/Keywords: Cancer; Combination Therapy; Cisplatin

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zhang, Q. (2017). A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment. (Thesis). University of Waterloo. Retrieved from http://hdl.handle.net/10012/11272

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zhang, Qinrong. “A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment.” 2017. Thesis, University of Waterloo. Accessed January 16, 2021. http://hdl.handle.net/10012/11272.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zhang, Qinrong. “A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment.” 2017. Web. 16 Jan 2021.

Vancouver:

Zhang Q. A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment. [Internet] [Thesis]. University of Waterloo; 2017. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10012/11272.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zhang Q. A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment. [Thesis]. University of Waterloo; 2017. Available from: http://hdl.handle.net/10012/11272

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of North Texas

21. Mirza Nasiri, Nooshin Mirza. Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging.

Degree: 2020, University of North Texas

URL: https://digital.library.unt.edu/ark:/67531/metadc1707253/

► With all the improvements in cancer treatments, multidrug resistance is still the major challenge in treating cancer. Cells can develop multidrug resistance (MDR) during or… (more)

▼ With all the improvements in cancer treatments, multidrug resistance is still the major challenge in treating cancer. Cells can develop multidrug resistance (MDR) during or after treatment, which will render the cancer cells resistant not only to the chemotherapy drug being used but also to many other structurally- and mechanically-different chemotherapeutics. In the first project, the main focus was on development of drug resistant cell lines by selection with taxol. Gene changes in the L1T2 cell line after treatment with Taxol was studied. Treatment of L1T2 cells with taxol leads to changes in the expression of ABC transporter proteins, whereas the combination of Taxol with protease inhibitors leads to increased efficacy via inhibition of P-glycoprotein (P-gp). In the second project, we showed that our innovatively-designed Au-loaded poly(lactide-co-glycolic acid) nanoparticles (GPLGA NPs) are able to cross biological barriers and deliver inside the cells without being recognized by the ABC protein transporter. (We focus specifically on P-gp-mediated drug efflux in a model of HEK cell lines.) The concentration of gold was measured using inductively-coupled plasma/mass spectrometry (ICP-MS) after 6- and 24-hour treatment of GPLGA NPs, which did not show significant increase of gold inside the cells in presence of the P-gp inhibitor valspodar. Cancer cells were treated with the GPLGA NPs for 24 hours and then irradiated 5 minutes at 1Wcm-2 using laser settings at 680 or 808 nm. Heat generation in cancer cells, after internalizing GPLGA NPs and laser irradiation, was significant irrespective of laser wavelength. The plasmomic heating response in this in vitro model can be a step closer to overcome MDR. Finally, for the third and last project represented in this dissertation, the focus was on the design and synthesis of innovative, biodegradable PLGA NPs, encapsulated with the platinum(II)-based non-organometallic/non-cyclometalated phosphorescent complex PTA = [Pt(ptp)2], a brightly phosphorescent complex (ptp = square-planar bis[3,5-bis(2-pyridyl)-1,2,4-triazolato]). Size-tunable, emission-polarized phosphorescent PTA-loaded PLGA NPs were synthesized using a single-emulsion, solvent evaporation technique. Photoluminescence characterization shows that PTA-loaded PLGA NPs exhibit strong and stable orange emission with peak maximum ~ 580 nm. The photoluminescence quantum yield (QY) of the synthesized PTA-PLGA NPs was evaluated at ~55%, which allows recording of images with a much better contrast than that with PTA in organic solvents without the PLGA (QY ~0.5% and ~0 emission polarization) or even that with typical fluorescent organic dyes like rhodamines. Advisors/Committee Members: Omary, Mohammad A, Gottesman, Michael M, Gryczynski, Ignacy, Simmons, Denise Perry, Marpu, Sreekar B, Slaughter, Legrande M.

Subjects/Keywords: Nanoparticle; Cancer Therapy an Imaging

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Mirza Nasiri, N. M. (2020). Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging. (Thesis). University of North Texas. Retrieved from https://digital.library.unt.edu/ark:/67531/metadc1707253/

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Mirza Nasiri, Nooshin Mirza. “Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging.” 2020. Thesis, University of North Texas. Accessed January 16, 2021. https://digital.library.unt.edu/ark:/67531/metadc1707253/.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Mirza Nasiri, Nooshin Mirza. “Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging.” 2020. Web. 16 Jan 2021.

Vancouver:

Mirza Nasiri NM. Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging. [Internet] [Thesis]. University of North Texas; 2020. [cited 2021 Jan 16]. Available from: https://digital.library.unt.edu/ark:/67531/metadc1707253/.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Mirza Nasiri NM. Novel Metal-Containing Nanoparticle Composites for Cancer Therapy and Imaging. [Thesis]. University of North Texas; 2020. Available from: https://digital.library.unt.edu/ark:/67531/metadc1707253/

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Minnesota

22. Zhao, Xianda. Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer.

Degree: PhD, Microbiology, Immunology and Cancer Biology, 2020, University of Minnesota

URL: http://hdl.handle.net/11299/216112

► Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of colorectal cancer (CRC) patients are resistant.… (more)

▼ Immune checkpoint blockade therapy (ICBT) has revolutionized the treatment and management of numerous cancers, yet a substantial proportion of colorectal cancer (CRC) patients are resistant. Most importantly, the mechanisms that cause ICBT resistance in CRC patients are mostly unclear. Both clinical and laboratory studies implied that both tumor cell-intrinsic factors and traditional cancer therapies (e.g., chemotherapy and oncogenic pathway-targeted therapy) have regulatory effects on anti-tumor immunity and ICBT efficacy. In the present thesis, we first characterized the pathological and immunological features of different pre-clinical CRC models. We reported the feasibility of using small animal endoscopy to establish mouse orthotopic colon tumors. We found that tumors grown orthotopically in the colon microenvironment develop better immune infiltration than tumors with the same genetic background growing in a subcutaneous microenvironment. These data indicated that the tissue microenvironment impacts anti-tumor immunity. Meanwhile, we observed that the endoscopy-guided cancer cell line-originated orthotopic CRC model is much more sensitive to ICBT over the subcutaneous model, making it not suitable for experiments that require ICBT-resistant tumors. This observation made us decide to use the subcutaneous tumor models, which are ICBT-resistant, for understanding cancer immunotherapy resistance. In the second section, we evaluated the impact of tumor-draining lymph nodes (TdLNs) and chemotherapy on ICBT efficacy. Specifically, we demonstrated TdLNs are critical for tumor antigen-specific T-cell response in early-stage tumors. However, TdLNs shift from an immunoreactive to an immunotolerant environment during tumor development. In mice with advanced primary tumors, TdLNs are not the major reservoir of tumor antigen-specific T cells. To evaluate the impacts of those immunotolerant TdLNs on ICBT response, we established a surgical model to mimic tumor recurrence in situ. We surgically removed the established primary tumors with or without concurrent TdLNs resection. Then, we inoculated secondary tumors, which are in the same lymphatic drainage area as the primary tumors, to mimic tumor recurrency. Notably, removing those immunotolerant TdLNs concurrently with established primary tumors did not affect the ICBT response on localized secondary tumors. In another set of experiments, we evaluated the impacts of chemotherapy (5-FU) on ICBT efficacy. We revealed that using 5-FU as induction treatment for ICBT increased tumor visibility to immune cells, decreased immunosuppressive cells in the tumor microenvironment, and limited chemotherapy-induced T-cell depletion. However, sustained chemotherapy impaired the efficacy of ICBT by suppressing the host immune system and depleting tumor-infiltrating T cells. Therefore, the sequential combination of chemotherapy with ICBT may result in a better response than the sustained chemotherapy and ICBT combination. Finally, we investigated how tumor cells regulate T-cell activation…

Subjects/Keywords: Cancer; Colon; Immunology; Therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zhao, X. (2020). Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer. (Doctoral Dissertation). University of Minnesota. Retrieved from http://hdl.handle.net/11299/216112

Chicago Manual of Style (16^th Edition):

Zhao, Xianda. “Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer.” 2020. Doctoral Dissertation, University of Minnesota. Accessed January 16, 2021. http://hdl.handle.net/11299/216112.

MLA Handbook (7^th Edition):

Zhao, Xianda. “Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer.” 2020. Web. 16 Jan 2021.

Vancouver:

Zhao X. Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer. [Internet] [Doctoral dissertation]. University of Minnesota; 2020. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/11299/216112.

Council of Science Editors:

Zhao X. Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer. [Doctoral Dissertation]. University of Minnesota; 2020. Available from: http://hdl.handle.net/11299/216112

Rutgers University

23. Karjoo Diarkhan, Zahra, 1980-. Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells.

Degree: PhD, Pharmaceutical Science, 2015, Rutgers University

URL: https://rucore.libraries.rutgers.edu/rutgers-lib/46367/

►

Developing an efficient and safe system for gene delivery is considered the bottleneck of gene therapy, where a successful delivery of the nucleic acid can… (more)

▼

Developing an efficient and safe system for gene delivery is considered the bottleneck of gene therapy, where a successful delivery of the nucleic acid can reverse a defective cellular pathway to normal, eradicate cancer at molecular level or simply make it more susceptible to current chemotherapies. Not only have the intracellular events played a crucial role for obtaining a successful gene delivery, but the interaction of nano-particles with extracellular factors should be studied as well. The goal of this study was to design, produce and optimize a non-viral gene delivery system for targeted delivery of nucleic acid such as reporter genes (e.g., green fluorescent protein) or therapeutic genes (e.g., suicide genes) to cancer cells. The system was designed in a way to be easily customized for different cancer types, still presenting a high level of targeted delivery. The first chapter of this thesis will focus on the concept of gene therapy and current systems used for this modality. Different types of vectors including viral and non-viral polymeric vectors will be discussed briefly and the advantages and disadvantages of each will be mentioned. We also discussed natured inspired biopolymers such as peptides and amino acid based vectors which are the fundamental premise of this study. In chapter II, the concept of suicide gene therapy will be explained. Additionally, the current enzyme/prodrug systems, different methods for delivery of suicide genes will be elaborated. In chapter III and IV, the new nanotechnology platform for targeted delivery of plasmid DNA to HER2-positive ovarian cancer cells and HER2-negative prostate cancer cells will be presented. In chapter III, the method for optimization of nanotechnology platform will be discussed and the features of optimized particles will be presented. Chapter IV explains the modification we introduced to the vectors’ primary structure to customize it for a different cell line. Also another method for optimization of amino-acid based vectors for in vivo delivery will be introduced. In these two chapters, the methods of designing and the efficiency of each vector to fulfill the expected goals as well as their safety will be discussed in details and supportive data will be presented.

Advisors/Committee Members: Hatefi, Arash (chair), Minko, Tamara (internal member), You, Guofeng (internal member), GOW, ANDREW (outside member).

Subjects/Keywords: Gene therapy; Cancer – Treatment; Nanoparticles

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Karjoo Diarkhan, Zahra, 1. (2015). Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells. (Doctoral Dissertation). Rutgers University. Retrieved from https://rucore.libraries.rutgers.edu/rutgers-lib/46367/

Chicago Manual of Style (16^th Edition):

Karjoo Diarkhan, Zahra, 1980-. “Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells.” 2015. Doctoral Dissertation, Rutgers University. Accessed January 16, 2021. https://rucore.libraries.rutgers.edu/rutgers-lib/46367/.

MLA Handbook (7^th Edition):

Karjoo Diarkhan, Zahra, 1980-. “Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells.” 2015. Web. 16 Jan 2021.

Vancouver:

Karjoo Diarkhan, Zahra 1. Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells. [Internet] [Doctoral dissertation]. Rutgers University; 2015. [cited 2021 Jan 16]. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/46367/.

Council of Science Editors:

Karjoo Diarkhan, Zahra 1. Customization and optimization of a histone h2a-based vector for targeted gene transfer to cancer cells. [Doctoral Dissertation]. Rutgers University; 2015. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/46367/

Georgia State University

24. Yang, Lingyun. Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions.

Degree: MS, Chemistry, 2017, Georgia State University

URL: https://scholarworks.gsu.edu/chemistry_theses/104

► Hypoxia Inducible Factors (HIFs) are very important transcription factors that can respond to low oxygen concentrations in the cellular environment. Inhibition of HIF’s transcriptional… (more)

Subjects/Keywords: hypoxia; hif-1; cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Yang, L. (2017). Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions. (Thesis). Georgia State University. Retrieved from https://scholarworks.gsu.edu/chemistry_theses/104

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Yang, Lingyun. “Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions.” 2017. Thesis, Georgia State University. Accessed January 16, 2021. https://scholarworks.gsu.edu/chemistry_theses/104.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Yang, Lingyun. “Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions.” 2017. Web. 16 Jan 2021.

Vancouver:

Yang L. Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions. [Internet] [Thesis]. Georgia State University; 2017. [cited 2021 Jan 16]. Available from: https://scholarworks.gsu.edu/chemistry_theses/104.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Yang L. Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions. [Thesis]. Georgia State University; 2017. Available from: https://scholarworks.gsu.edu/chemistry_theses/104

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of New South Wales

25. Armstrong, Luke. Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic.

Degree: Biotechnology & Biomolecular Sciences, 2016, University of New South Wales

URL: http://handle.unsw.edu.au/1959.4/56172 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:40188/SOURCE02?view=true

► Mesothelioma is a cancer of the pleural cavity in the lungs. The prognosis for people who develop this type of cancer is incredibly low, with… (more)

▼ Mesothelioma is a cancer of the pleural cavity in the lungs. The prognosis for people who develop this type of cancer is incredibly low, with survival rates of less than 18 months for nearly all patients. Chemotherapy so far has not improved the quality of life significantly for mesothelioma patients. This means new methods of treating the disease are required.The EnGeneIC Dream Vector™ (EDV) is a 400nm bacterially derived nanocell which can be loaded with either chemotherapeutic drugs or genetic material and targeted with bispecific proteins to target cancer cells directly and deliver the treatment specifically to these cells. For malignant pleural mesothelioma, a miR-16 mimic RNA molecule was loaded into the EDVs in order to prevent cell proliferation and promote apoptosis.In this study, several non-invasive methods were investigated to determine their value as markers pre and post EDV treatment in mesothelioma. First, circulating tumour cells (CTCs) were extracted from the whole blood samples of mesothelioma patients for diagnostic purposes based on their concentration. To corroborate this data, the biomarker mesothelin was also quantified from serum samples of these patients as well as in tissue culture experiments. Additionally, macrophages from tumour microenvironments in murine models of mesothelioma were isolated and identified based on their cell surface receptors. Methods for the identification of different classes of macrophage were developed to monitor their concentrations in the tumour microenvironment pre and post EDV treatment. This study found no significant results for the change in CTC concentrations of mesothelioma patients or the differentiation of macrophages. Surprisingly, a significant increase in mesothelin levels of cultured mesothelioma cells occurred when cell death was achieved. The trend in the patients matched this increase but was not significant. Advisors/Committee Members: Marquis, Christopher, Biotechnology & Biomolecular Sciences, Faculty of Science, UNSW, MacDiarmid, Jennifer, UNSW.

Subjects/Keywords: Cancer; Mesothelioma; EDV; Targeted therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Armstrong, L. (2016). Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic. (Masters Thesis). University of New South Wales. Retrieved from http://handle.unsw.edu.au/1959.4/56172 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:40188/SOURCE02?view=true

Chicago Manual of Style (16^th Edition):

Armstrong, Luke. “Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic.” 2016. Masters Thesis, University of New South Wales. Accessed January 16, 2021. http://handle.unsw.edu.au/1959.4/56172 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:40188/SOURCE02?view=true.

MLA Handbook (7^th Edition):

Armstrong, Luke. “Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic.” 2016. Web. 16 Jan 2021.

Vancouver:

Armstrong L. Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic. [Internet] [Masters thesis]. University of New South Wales; 2016. [cited 2021 Jan 16]. Available from: http://handle.unsw.edu.au/1959.4/56172 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:40188/SOURCE02?view=true.

Council of Science Editors:

Armstrong L. Studies on biomarkers of Malignant Pleural Mesothelioma to determine their value in assessing a targeted cancer therapeutic. [Masters Thesis]. University of New South Wales; 2016. Available from: http://handle.unsw.edu.au/1959.4/56172 ; https://unsworks.unsw.edu.au/fapi/datastream/unsworks:40188/SOURCE02?view=true

University of Texas – Austin

26. -7017-2332. Development of human enzymes for amino acid depletion therapy.

Degree: PhD, Cell and Molecular Biology, 2016, University of Texas – Austin

URL: http://dx.doi.org/10.26153/tsw/10061

► Heterologous enzymes have been investigated for a variety of therapeutic purposes, including targeted enzymatic amino acid depletion for the treatment of a variety of cancers.… (more)

▼ Heterologous enzymes have been investigated for a variety of therapeutic purposes, including targeted enzymatic amino acid depletion for the treatment of a variety of cancers. However, because heterologous enzymes are foreign (non-human), they elicit immune responses. Human enzymes are naturally tolerated by the immune system and are expected to be non-immunogenic. Unfortunately, the human genome does not encode enzymes with the requisite pharmacological and catalytic properties necessary for therapeutic purposes. In this work, we have used a variety of strategies for the development of novel human enzymes for the therapeutic depletion of specific amino acids. The availability of a human enzyme candidate with the requisite substrate specificity largely dictates the strategy to select for the development of a therapeutic. In the event that no human enzyme with the desired specificity is available, the engineering of human enzymes that catalyze a related biotransformation is an available option. As part of this dissertation, we characterized the human cysteine sulfinic acid decarboxylase (hCSAD) with the intent of using it as a scaffold to engineer enzymes with a therapeutically relevant specificity. We performed a sequence, structural and mutational analysis of hCSAD and implemented rational design mutagenesis to generate hCSAD variants with a de novo L-Serine decarboxylase activity. This dissertation also reports work on the human asparaginase-like protein 1 (hASRGL1). Bacterial asparaginases are in clinical use for the treatment of acute lymphoblastic leukemia (ALL), however their use can be associated with significant side effects. hASRGL1 is a human isoaspartyl peptidase which also exhibits asparaginase activity. Being a native human protein, hASRGL1 is expected to have a non-immunogenic profile; however, the poor kinetic properties with respect to L-Asn hydrolysis limit its use. To convert hASRGL1 into a useful drug candidate, we developed a facile process for its recombinant expression; in particular, we circumvented the autocatalytic processing step which is required to form the active enzyme. In addition, we used a scheme of random mutagenesis, high-throughput screening and NGS analysis that led to the identification of hASRGL1 variants with improved asparaginase activity and stability, which we evaluated for their in vitro efficacy against ALL cell lines. Advisors/Committee Members: Georgiou, George (advisor), Stone, Everett M (committee member), DiGiovanni, John (committee member), Tiziani, Stefano (committee member), Upton, Jason W (committee member), Zhang, Yan J (committee member).

Subjects/Keywords: Human enzymes; Cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

-7017-2332. (2016). Development of human enzymes for amino acid depletion therapy. (Doctoral Dissertation). University of Texas – Austin. Retrieved from http://dx.doi.org/10.26153/tsw/10061

Note: this citation may be lacking information needed for this citation format:
Author name may be incomplete

Chicago Manual of Style (16^th Edition):

-7017-2332. “Development of human enzymes for amino acid depletion therapy.” 2016. Doctoral Dissertation, University of Texas – Austin. Accessed January 16, 2021. http://dx.doi.org/10.26153/tsw/10061.

Note: this citation may be lacking information needed for this citation format:
Author name may be incomplete

MLA Handbook (7^th Edition):

-7017-2332. “Development of human enzymes for amino acid depletion therapy.” 2016. Web. 16 Jan 2021.

Note: this citation may be lacking information needed for this citation format:
Author name may be incomplete

Vancouver:

-7017-2332. Development of human enzymes for amino acid depletion therapy. [Internet] [Doctoral dissertation]. University of Texas – Austin; 2016. [cited 2021 Jan 16]. Available from: http://dx.doi.org/10.26153/tsw/10061.

Note: this citation may be lacking information needed for this citation format:
Author name may be incomplete

Council of Science Editors:

-7017-2332. Development of human enzymes for amino acid depletion therapy. [Doctoral Dissertation]. University of Texas – Austin; 2016. Available from: http://dx.doi.org/10.26153/tsw/10061

Note: this citation may be lacking information needed for this citation format:
Author name may be incomplete

University of Melbourne

27. Au-Yeung, George. Cyclin E1 as a therapeutic target in high grade serous ovarian cancer.

Degree: 2017, University of Melbourne

URL: http://hdl.handle.net/11343/191772

► The central theme of this thesis is developing therapeutic strategies to selectively target CCNE1 amplified high grade serous ovarian cancer (HGSC). Patients with CCNE1 amplified… (more)

▼ The central theme of this thesis is developing therapeutic strategies to selectively target CCNE1 amplified high grade serous ovarian cancer (HGSC). Patients with CCNE1 amplified HGSC represent a key unmet clinical need given that they are associated with primary treatment resistance and poor clinical outcome. Novel therapeutic strategies are urgently required in order to provide these patients with additional treatment options. Using short interfering RNA and short hairpin RNA, I demonstrated selective sensitivity of CCNE1 amplified HGSC to CDK2 gene suppression. However, I did not demonstrate similar amplicon dependent sensitivity to dinaciclib, a potent small molecule inhibitor of multiple CDKs. In order to identify drug combinations that would synergise with dinaciclib, I performed a high throughput compound screen in CCNE1 amplified HGSC cell lines. I identified a combination of dinaciclib and MK-2206, an AKT inhibitor, that was selectively synergistic in in vitro and in vivo models of CCNE1 amplified HGSC. CCNE1 and AKT2 were noted to be co-amplified in primary HGSC samples, and a number of genes in the AKT pathway were found to be required in CCNE1 amplified HGSC cell lines. Furthermore, over-expression of cyclin E1 and AKT isoforms resulted in uncontrolled growth characteristics in TP53-mutant fallopian tube secretory cells, the proposed cell of origin for HGSC. Taken together, these findings suggest that co-operative interaction between CCNE1 and the AKT pathway in HGSC may be exploited therapeutically. I also explored the potential mechanisms of resistance to CDK inhibitors by generating cell lines resistant to dinaciclib. Dinaciclib in combination with multiple BH3-mimetic compounds was noted to be synergistic in CDK-inhibitor resistant cell lines. Upregulation of multiple anti-apoptotic genes was observed in resistant cell lines compared to parental sensitive cell lines, suggesting that this is a potential mechanism of resistance to CDK inhibitors. Targeting homologous recombination (HR) may also be a therapeutic option in CCNE1 amplified HGSC. Proteasome inhibitors such as bortezomib have been shown to be indirect inhibitors of HR, and I showed that CCNE1 amplified cell lines were highly sensitive to bortezomib and MLN9708, a second generation proteasome inhibitor. Potential synergistic combinations with bortezomib were identified in a high throughput compound screen, including a number of HDAC inhibitors, suggesting a possible class effect.

Subjects/Keywords: Ovarian cancer; Molecular targets; Cancer therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Au-Yeung, G. (2017). Cyclin E1 as a therapeutic target in high grade serous ovarian cancer. (Doctoral Dissertation). University of Melbourne. Retrieved from http://hdl.handle.net/11343/191772

Chicago Manual of Style (16^th Edition):

Au-Yeung, George. “Cyclin E1 as a therapeutic target in high grade serous ovarian cancer.” 2017. Doctoral Dissertation, University of Melbourne. Accessed January 16, 2021. http://hdl.handle.net/11343/191772.

MLA Handbook (7^th Edition):

Au-Yeung, George. “Cyclin E1 as a therapeutic target in high grade serous ovarian cancer.” 2017. Web. 16 Jan 2021.

Vancouver:

Au-Yeung G. Cyclin E1 as a therapeutic target in high grade serous ovarian cancer. [Internet] [Doctoral dissertation]. University of Melbourne; 2017. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/11343/191772.

Council of Science Editors:

Au-Yeung G. Cyclin E1 as a therapeutic target in high grade serous ovarian cancer. [Doctoral Dissertation]. University of Melbourne; 2017. Available from: http://hdl.handle.net/11343/191772

Rutgers University

28. Salman Noori, Faranak, 1986-. Stem cell-based ovarian cancer suicide gene therapy.

Degree: PhD, Pharmaceutical Science, 2015, Rutgers University

URL: https://rucore.libraries.rutgers.edu/rutgers-lib/48643/

►

Cancer is a leading cause of death worldwide, resulting in 8.2 million deaths in 2012. Tumor suicide gene therapy is among the novel targeted therapeutics… (more)

▼

Cancer is a leading cause of death worldwide, resulting in 8.2 million deaths in 2012. Tumor suicide gene therapy is among the novel targeted therapeutics that has demonstrated promising results. There are two important factors that specify the efficiency and safety of the suicide gene therapy systems. One is vector safety and efficiency and the other enzyme/prodrug anticancer efficacy. Among the vectors employed for delivery of therapeutics, mesenchymal stem cells (MSCs) have attracted tremendous amount of attention due to their unique features such as inherent tumor tropism and low immunogenicity. The objective of this research was to take advantage of MSCs as cell-based vectors to develop an efficient and safe suicide gene therapy system for cancer. As a first step towards achieving the objective, I engineered a panel of MSCs that were genetically modified to express five different suicide genes and compared their anti-tumor efficiency in vitro and in vivo. Among the enzyme/prodrug systems tested, genetically modified MSCs that expressed yeast cytosine deaminase enzyme (yCD-UPRT) in combination with prodrug 5-fluorocytosine (5FC) demonstrated the highest anti-tumor efficacy. In the next step we focused on developing a safe and efficient method for stem cell engineering. Since current commercially available transfection agents are inefficient and toxic to MSCs, I made an attempt to develop a safe and efficient gene delivery system suitable for MSC engineering. Using a previously developed vector in Dr. Hatefi’s lab as a template, I recombinantly engineered a new vector for MSC transfection. This vector is comprised of a cell penetrating peptide for penetration into MSCs, four histone H2A repeats to condense plasmid DNA (pDNA) into nanosize particles and a fusogenic peptide named GALA to facilitate endosomal escape. The results of this study illustrated that the newly developed recombinant vector could efficiently and safely transfect MSCs. In conclusion we not only successfully developed a safe and efficient method for stem cell engineering but also identified an enzyme/prodrug system that could be used for effective treatment of ovarian cancer.

Advisors/Committee Members: Minko, Tamara (chair).

Subjects/Keywords: Cancer – Gene therapy; Ovaries – Cancer; Stem cells

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Salman Noori, Faranak, 1. (2015). Stem cell-based ovarian cancer suicide gene therapy. (Doctoral Dissertation). Rutgers University. Retrieved from https://rucore.libraries.rutgers.edu/rutgers-lib/48643/

Chicago Manual of Style (16^th Edition):

Salman Noori, Faranak, 1986-. “Stem cell-based ovarian cancer suicide gene therapy.” 2015. Doctoral Dissertation, Rutgers University. Accessed January 16, 2021. https://rucore.libraries.rutgers.edu/rutgers-lib/48643/.

MLA Handbook (7^th Edition):

Salman Noori, Faranak, 1986-. “Stem cell-based ovarian cancer suicide gene therapy.” 2015. Web. 16 Jan 2021.

Vancouver:

Salman Noori, Faranak 1. Stem cell-based ovarian cancer suicide gene therapy. [Internet] [Doctoral dissertation]. Rutgers University; 2015. [cited 2021 Jan 16]. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/48643/.

Council of Science Editors:

Salman Noori, Faranak 1. Stem cell-based ovarian cancer suicide gene therapy. [Doctoral Dissertation]. Rutgers University; 2015. Available from: https://rucore.libraries.rutgers.edu/rutgers-lib/48643/

University College Cork

29. Sadadcharam, Mira. Expanding the use of electroporation from cutaneous to intraluminal and systemic applications.

Degree: 2015, University College Cork

URL: http://hdl.handle.net/10468/3484

► Cancer is a global phenomenon transcending the boundaries of age, race, geography and socioeconomic background. As our understanding of cancer cell biology has improved, we… (more)

▼ Cancer is a global phenomenon transcending the boundaries of age, race, geography and socioeconomic background. As our understanding of cancer cell biology has improved, we have developed a growing appreciation of cancer as a systemic disease. However, our improved understanding has been matched by cancer cell evolution and it is becoming increasingly clear that the future of anti-cancer therapies lies in a multi-modal approach. In this thesis, we adopted a “three-legged stool” approach to anti-cancer therapy. The first leg encompasses primary tumour ablation. We developed the EndoVe device, enabling endoscopic electroporation of gastrointestinal tissues and tumours. We conducted a pre-clinical evaluation of the EndoVe prior to a phase I/II clinical study and validated the efficacy of the system in the treatment of cutaneous murine gastrointestinal tumours. In addition, we established the safety and utility of endoscopically-delivered electroporation through evaluation in a porcine model and by treating canine colorectal tumours. The second leg of our stool involved immunotherapy. We opted for a combination regime of Treg depletion and immunotherapy with the cytokine, pGMCSF-B7.1. While we observed a modest but significant improvement of primary tumour burden, the combination regime had the remarkable effect of eradicating pre-existing, established lung metastases when compared to the use of either treatment alone. The potential clinical implications of this should not be understated as nine out of ten cancer deaths are directly attributable to metastatic disease burden. The third and final leg of our anti-cancer strategy involved the development of a DNA-based enhanced expression vector (pEEV), with improved expression capabilities across a range of tissue histologies over standard non-viral DNA vectors. Following on from this observation, we then utilised this pEEV vector system in combination with the immune cytokine GMCSF-B7.1 leading to robust recruitment of immune effector cells with consequent potent, durable and transferable tumour antigen-specific responses. Advisors/Committee Members: Soden, Declan, Forde, Patrick.

Subjects/Keywords: Electroporation; Electrochemotherapy; EndoVe; Cancer immunogene therapy; Immune therapy; Gene therapy

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Sadadcharam, M. (2015). Expanding the use of electroporation from cutaneous to intraluminal and systemic applications. (Thesis). University College Cork. Retrieved from http://hdl.handle.net/10468/3484

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Sadadcharam, Mira. “Expanding the use of electroporation from cutaneous to intraluminal and systemic applications.” 2015. Thesis, University College Cork. Accessed January 16, 2021. http://hdl.handle.net/10468/3484.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Sadadcharam, Mira. “Expanding the use of electroporation from cutaneous to intraluminal and systemic applications.” 2015. Web. 16 Jan 2021.

Vancouver:

Sadadcharam M. Expanding the use of electroporation from cutaneous to intraluminal and systemic applications. [Internet] [Thesis]. University College Cork; 2015. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10468/3484.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Sadadcharam M. Expanding the use of electroporation from cutaneous to intraluminal and systemic applications. [Thesis]. University College Cork; 2015. Available from: http://hdl.handle.net/10468/3484

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

University of Waterloo

30. Zargar, Bahram. A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting.

Degree: 2014, University of Waterloo

URL: http://hdl.handle.net/10012/9014

► Development of a drug delivery agent that selectively targets and destroys tumor cells with minimal toxicity to normal tissues is a major challenge in cancer… (more)

▼ Development of a drug delivery agent that selectively targets and destroys tumor cells with minimal toxicity to normal tissues is a major challenge in cancer therapy. It has been known for more than 60 years that anaerobic bacteria such as Clostridium can selectively colonize inside the necrotic core of solid tumors. Inoculation of a tumor by wild type Clostridium results in colonization of the necrotic core and consequently significant tumor destruction. This treatment strategy is hampered by the fact that the outer rim of the tumor is typically viable, and so does not present an anaerobic environment. As a result, colonization by Clostridium is unlikely to lead to complete tumor regression, since tumor regrowth occurs from the remaining outer viable rim, as evidenced by clinical trials. This project aims to address the problem of regrowth by developing a novel selectively aerotolerant strain of Clostridium that cannot colonize inside healthy tissue, but that could grow in the viable rim of an infected tumor. We have engineered a gene coding for an aerotolerance enzyme into Clostridium sporogenes. To couple the selective expression of this gene to tumor colonization, it can be placed under the control of a promoter activated by a synthetic quorum sensing circuit. This document describes the foundational work that will allow this system to be implemented. A suitable strain of C. sporogenes was selected, and a cloning technique (via conjugation with E. coli) was implemented. Expression of the aerotolerance enzyme and a synthetic quorum sensing circuit were verified in engineered colonies, and appropriate function was confirmed in both cases. Additionally, a model-based design exercise was carried out in order to better understand the system behavior and to identify key parameters for controlling the bacterial population. This analysis was based on mathematical models of the quorum-sensing circuit and of bacterial growth in the tumor environment. Sensitivity analysis reveals the design parameters that have the most significant impact on the extent and specificity of colonization of the viable rim, and thus provides insights into efficient design of the synthetic mechanism.

Subjects/Keywords: Synthetic Biology; Bacteria Mediated Cancer Therapy; Cancer; Clostridium Mediated Cancer Therapy; Quorum Sensing; S. aureus

Record Details Similar Records Cite « Share

❌

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6^th Edition):

Zargar, B. (2014). A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting. (Thesis). University of Waterloo. Retrieved from http://hdl.handle.net/10012/9014

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16^th Edition):

Zargar, Bahram. “A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting.” 2014. Thesis, University of Waterloo. Accessed January 16, 2021. http://hdl.handle.net/10012/9014.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7^th Edition):

Zargar, Bahram. “A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting.” 2014. Web. 16 Jan 2021.

Vancouver:

Zargar B. A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting. [Internet] [Thesis]. University of Waterloo; 2014. [cited 2021 Jan 16]. Available from: http://hdl.handle.net/10012/9014.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Zargar B. A Synthetic Biology Approach to Bacteria Mediated Tumor Targeting. [Thesis]. University of Waterloo; 2014. Available from: http://hdl.handle.net/10012/9014

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

		in
And / Or
		in
And / Or
		in
And / Or
		in

Open Access Theses and Dissertations